Table 3.
Influence of FACBC on Radiotherapy Treatment and Treatment Field Recommendations
| Post-Fluciclovine Decision | Decision Change n (%) | P-Value* | |||
|---|---|---|---|---|---|
| Pre-Fluciclovine Decision | |||||
| Radiotherapy Decision (n=42) | Offer XRT | No XRT | |||
| Offer XRT | 40 | 2** | 2 (4.8) | P = 0.15 | |
| No XRT | 0 | 0 | 0 (0) | ||
| Radiotherapy Field (n=40)*** | Prostate only | Prostate + Pelvis | |||
| Prostate only (n=26) | 15 | 11** | 11 (27.5) | P<0.0001 | |
| Prostate + Pelvis (n=14) | 4** | 10 | 4 (10.0) | ||
| Overall XRT Decision (n=42) | Prostate | Prostate + Pelvis | No XRT | ||
| XRT to prostate | 15 | 11** | 0 | 11(26.2) | P<0.0001 |
| XRT to prostate + pelvis | 4** | 10 | 2** | 6 (14.3) | |
| No XRT | 0 | 0 | 0 | 0 (0) | |
*
Statistical significance of overall decision changes calculated using Clopper-Pearson (exact) binomial method
**
Decision Change
***
2 patients excluded as the final decision was not to give radiotherapy XRT Radiotherapy